Orbit Discovery 

A new spinout from the University of Oxford – has been launched to use the technology developed at Oxford’s Weatherall Institute of Molecular Medicine by Professors Graham Ogg and Terence Rabbitts.

Orbit Discovery has raised seed funding to commercialise technology which will help to identify targeted, affordable therapeutic drugs known as peptides. Oxford Sciences Innovation, the £320m investment company established to provide capital and scaling expertise to Oxford spin-outs, is the lead investor in the new company.  Other investors include the Oxford Technology and Innovations EIS Fund led by George Robinson and the OT(S)EIS fund managed by Oxford Technology management, which has been making science investments around Oxford for 30 years.

Orbit Discovery will establish a screening platform to identify robust peptide drug candidates for both internal industry drug discovery programs and via collaborative research. Enquiries for commercial collaborations or licencing opportunities should be directed to the CEO Dr Alex Batchelor.